系统性红斑狼疮患者静脉血栓栓塞症预测模型的开发与外部验证
基于中国系统性红斑狼疮治疗与研究组队列,在4502例患者中开发SLE-VTE评分(含11个变量),并在3780例患者中外部验证,预测6个月内VTE风险的AUC分别为0.947和0.808。根据净获益与预测概率阈值,作者推荐对高风险(≥1.03%)SLE患者每年筛查VTE。
要点
- SLE-VTE评分含11个变量,开发队列AUC 0.947,外部验证队列AUC 0.808。
- 作者推荐对高风险(预测概率≥1.03%)SLE患者每年筛查VTE。
- 该评分有助于识别可能从血栓预防中获益的高VTE风险SLE患者。
核心结论
- 多种因素与SLE患者VTE发生相关,所提出的SLE-VTE风险评分能准确预测VTE风险,并有助于识别可能从血栓预防中获益的高VTE风险SLE患者。
研究设计与样本
- 基于中国系统性红斑狼疮治疗与研究组队列(CSTAR)2009年1月至2020年1月的4502例SLE患者开发临床预测模型,并在CSTAR 2020年1月至2022年1月的3780例SLE患者中进行外部验证。
- 获取基线数据,随访期间记录VTE事件,采用多变量逻辑回归和最小绝对收缩与选择算子开发预测6个月内VTE风险的模型,并建立SLE-VTE评分和列线图。
主要发现
- 开发队列共纳入4502例患者,其中135例发生VTE事件。
- 最终预测模型(SLE-VTE评分)纳入11个变量:性别、年龄、体重指数、高脂血症、低白蛋白血症、C反应蛋白、抗β2GPI抗体、狼疮抗凝物、肾脏受累、神经系统受累和羟氯喹,开发队列(n=4502)和外部验证队列(n=3780)的曲线下面积分别为0.947和0.808。
关键数值与推荐
- 根据净获益和预测概率阈值,作者推荐对高风险(≥1.03%)SLE患者每年筛查VTE。
- SLE-VTE评分包含11个变量,开发队列AUC为0.947,外部验证队列AUC为0.808。
临床怎么用
- 作者推荐对高风险(预测概率≥1.03%)SLE患者每年筛查VTE。
- 作者认为SLE-VTE风险评分有助于识别可能从血栓预防中获益的高VTE风险SLE患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Patients with systemic lupus erythematosus (SLE) have an increased risk of venous thromboembolism (VTE). We conducted this study to develop a risk score algorithm for VTE in patients with SLE that provides individualised risk estimates. METHODS: We developed a clinical prediction model of VTE in 4502 patients with SLE based on the Chinese SLE Treatment and Research group cohort (CSTAR) from January 2009 to January 2020 and externally validated in 3780 patients with SLE in CSTAR from January 2020 to January 2022. Baseline data were obtained and VTE events were recorded during the follow-up. The prediction model was developed to predict VTE risk within 6 months in patients with SLE, using multivariate logistic regression and least absolute shrinkage and selection operator. SLE-VTE score and nomogram were established according to the model. RESULTS: A total of 4502 patients included in the development cohort, 135 had VTE events. The final prediction model (SLE-VTE score) included 11 variables: gender, age, body mass index, hyperlipidaemia, hypoalbuminaemia, C reactive protein, anti-β2GPI antibodies, lupus anticoagulant, renal involvement, nervous system involvement and hydroxychloroquine, with area under the curve of 0.947 and 0.808 in the development (n=4502) and external validation cohort (n=3780), respectively. According to the net benefit and predicted probability thresholds, we recommend annual screening of VTE in high risk (≥1.03%) patients with SLE. CONCLUSION: Various factors are related to the occurrence of VTE in patients with SLE. The proposed SLE-VTE risk score can accurately predict the risk of VTE and help identify patients with SLE with a high risk of VTE who may benefit from thromboprophylaxis.
引用
- You H, Zhao J, Zhang M, et al. Development and external validation of a prediction model for venous thromboembolism in systemic lupus erythematosus. RMD Open. 2023. PMID: 37996129. doi:10.1136/rmdopen-2023-003568
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。